32 C
Vientiane
Friday, May 9, 2025
spot_img
Home Blog Page 707

Unleash Your Children’s Potential: iCare Eyecare’s Solutions Enhance Learning and Sports Engagement

iCare Eyecare’s Mission: Keep your eyes, sharpen your edge, and promote your wellness

HONG KONG SAR – Media OutReach Newswire – 7 February 2025 – With the rise of digital media, screen devices have become an integral part of everybody’s life, and e-learning is an inevitable trend in school. However, this has posed unprecedented challenges to the visual health of everyone, especially children. According to a recent study by The Chinese University of Hong Kong, the prevalence of myopia among children in Hong Kong has reached a record high. Notably, after the pandemic, the myopia rate among six-year-olds surged from 13.9% pre-pandemic to 25%, nearly doubling. This trend has raised widespread concerns as myopia is now considered a multifaceted condition that significantly impacts eye health in the long run. In addition to myopia, children may also suffer from other refractive errors (such as hyperopia and astigmatism), strabismus, and various levels of dynamic visual impairments, such as convergence insufficiency (CI). These eye conditions can significantly hamper children’s reading, learning, concentration, and sports performance, potentially affecting their overall development. Parents must be aware of these issues and seek professional analysis to ensure their child’s vision is not a barrier to their success.

Experience analysis combined with advanced equipment such as Optical Coherence Tomography (OCT) and automated eye movement analysis systems
Experience analysis combined with advanced equipment such as Optical Coherence Tomography (OCT) and automated eye movement analysis systems

Studies in the United States indicate that 1 in 4 children experiences some form of visual impairment, which can sometimes be misdiagnosed as neurodevelopmental disorders such as dyslexia, attention deficit hyperactivity disorder (ADHD), or other learning disabilities. Misdiagnosis, as such, can severely impact a child’s academic and motor development. In Hong Kong, families often lack awareness of the connection between vision problems and learning or motor skills. Children with visual impairments may display short attention spans, skip lines when reading, have difficulty retaining information, experience discomfort or fatigue, or even avoid reading altogether, behaviors resembling ADHD. Moreover, convergence insufficiency (CI) occurs more frequently among ADHD patients than in the general population. Apart from academic hardship, various vision disabilities can also lead to poor depth perception, meager eye tracking proficiency, and below-par visual signal brain processing, collectively translating to low performance in sports such as ball games. This underlines the urgent need for parents to be aware of these issues and seek professional analysis to ensure their child’s vision is not a barrier to their success.

Dynamic and Sports Vision Training to Sharpen Your Edge

To improve children’s overall visual function, iCare Eyecare offers evidence-based myopia management services, customized orthokeratology (OK lenses) treatments, unique dynamic and sports vision analysis and training programs. These services aim to promote children’s long-term eye health, improve overall visual function, and bolster their learning and athletic performance.

At iCare Eyecare, our services are directed by Dr. Marco, Ph.D., a visiting lecturer at The Hong Kong Polytechnic University School of Optometry, and delivered by his professional team. With years of experience and a deep understanding of vision science, Dr. Marco and his team employ diverse advanced technologies, such as Optical Coherent Tomography (OCT), non-invasive optical ocular biometry, corneal topography, and automated eye movement analysis systems.Their expertise, combined with state-of-the-art technologies, enables unmatched comprehensive optometric and visual function assessments, creating personalized eye care plans and professionally tailored vision training recommendations for every child.

Maintaining good visual health and dynamic vision abilities is crucial in today’s ever-changing world. For instance, in emergencies, well-developed visual skills can help individuals anticipate and react to situations more quickly, potentially saving lives! Both static and dynamic visual skills are essential in daily life, whether reading or participating in sports like football or basketball. With scientific analysis, individuals can now better understand their sports vision capabilities. Most importantly, customized and effective training can be carried out to sharpen their edge in case of a flaw. This knowledge empowers parents to take proactive steps to ensure their child’s visual health is not overlooked.

iCare Eyecare Professional Services Include:

1. Myopia Management for Children: Professional advice and evidence-based practice to control myopia progression.
2. Dynamic and Sports Vision Analysis and Training: Comprehensive assessments and specific training to enhance visual skills.
3. Personalized Eyeglasses and Contact Lens Customization: Tailored solutions to optimize visual outcome.

Founder of iCare Eyecare Dr. Marco

Dr. Marco, the founder of iCare Eyecare, is a highly experienced registered optometrist (Part I) with a strong background in clinical practice and basic science research. He graduated with first-class honors from the School of Optometry at The Hong Kong Polytechnic University and holds a Ph.D. in Vision Science, making him a physiologist.

Dr. Marco previously served as a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai in New York City (specializing in dry eye disease and cataracts) and as a Research Assistant Professor at the University of Hong Kong. He also enjoys teaching and is a visiting lecturer in myopia science at the Hong Kong Polytechnic University School of Optometry and HKU SPACE.

The establishment of iCare Eyecare stems from Dr. Marco’s vision to expand the role of optometrists as the first line of defense for the eye and overall health. His “family optometrist” concept aims to protect every family member’s health.

To promote public awareness, Dr. Marco is an expert contributor to the popular parenting media Oh!爸媽, sharing valuable eye care tips. His dedication to sports and vision have led him to join the International Sports Vision Association (ISVA) and earn a professional diploma in sports nutrition from the Barcelona Innovation Hub (BIHUB). By integrating cutting-edge vision science and nutrition, Dr. Marco helps students and athletes improve their focus, overall vision abilities, academic performance, and athletic achievements.
Hashtag: #iCare #iCareEyecare

The issuer is solely responsible for the content of this announcement.

About iCare Eyecare

Founded in 2017, iCare Eyecare’s vision is to provide Hong Kong residents with the highest-quality primary optometric eyecare. Their detail-oriented services go beyond meeting your visual needs but committed to keeping your eyes, sharpening your edge, and promoting your wellness!
Address:Suite 1317, 13/F, Ocean Centre, Harbour City, 5 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong
Tel︰+852 3188 4643
Website:
Facebook:
Instagram:

BRI UMKM EXPO(RT) 2025 Officially Concludes, Attracting Over 63,000 Visitors and Securing USD 90.6 Million in Export Contracts

JAKARTA, Indonesia, Feb. 7, 2025 /PRNewswire/ — PT Bank Rakyat Indonesia (Persero) Tbk. (IDX: BBRI) successfully concluded BRI UMKM EXPO(RT) 2025, reinforcing its commitment to empowering MSMEs and expanding their global market reach. Held from January 30 to February 2, 2025, at ICE BSD City, the event attracted over 63,000 visitors, generated IDR 38.9 billion in transactions, and secured USD 90.6 million in export contracts through business matching. The closing ceremony was led by BRI President Director Sunarso.

BRI President Director Sunarso at BRI UMKM EXPO(RT) 2025 Closing Ceremony
BRI President Director Sunarso at BRI UMKM EXPO(RT) 2025 Closing Ceremony

A Platform for Global MSME Expansion

With the theme “Broadening MSME’s Global Outreach”, the event showcased 1,000 top Indonesian MSMEs ready for the international market. The closing ceremony was attended by BRI Vice President Director Catur Budi Harto. BRI President Director Sunarso highlighted the expo’s success in raising awareness of local MSME products, exceeding its initial target of 50,000 visitors.

By February 1, 2025, transactions hit IDR 38.9 billion, exceeding expectations. Sunarso reaffirmed BRI’s commitment to MSMEs, with business matching continuing through 2025 in partnership with the Ministry of Trade, holding twice-monthly sessions to boost exports.

This year’s BRI UMKM EXPO(RT) 2025 saw the participation of 506 registered buyers from 34 countries, significantly exceeding the initial target of 94 buyers from 33 countries.

So far, 166 MSMEs have engaged in 270 business meetings, one of the standout success stories is PT Siger Jaya Abadi, which secured a USD 13.05 million export deal with Bluestar Food Corporation, USA.

BRI UMKM Awards: Honoring Top MSMEs

BRI recognized outstanding businesses in three categories:

1. Top Deals on Business Matching

For MSMEs achieving the highest potential transactions in business matching sessions:

  • Bintang Kita Kemuliaan (Food & Beverage)
  • Albasi Karang Layung (Home Décor & Craft)
  • Gula Aren Temon (Food & Beverage)

2. Newcomers on Business Matching

For first-time exporters who successfully secured international buyers:

  • Rumah Atsiri Indonesia (Healthcare & Wellness)
  • Minyak Sacha Inchi (Food & Beverage)
  • Organic Center (Food & Beverage)

3. Best Expo

For MSMEs demonstrating outstanding export readiness and digital adoption:

  • Sila Agri Inovasi (Food & Beverage)
  • Pelita Lumpang Mas (Food & Beverage)
  • Restu Mande (Food & Beverage)

These awards highlight BRI’s commitment to empowering MSMEs globally while advancing financial literacy and inclusion.

For more details on BRI UMKM EXPO(RT) 2025, visit briumkmexport.com.

For more information about BANK BRI, visit www.bri.co.id.

Village in eastern China celebrates Start of Spring

QUZHOU, China, Feb. 7, 2025 /PRNewswire/ — This is a report from China.org.cn.

Miaoyuan village in Quzhou city, Zhejiang province, held ritual activities on Monday to celebrate Lichun, or the Start of Spring, the first of the 24 solar terms in the Chinese lunar calendar.

In the morning, a ritual ceremony was held at a local temple, where villagers presented flower baskets and sacrificial offerings to Goumang, the God of Spring, praying for harvest and prosperity in the coming year.

During the ceremony, the ritual of Whipping the Spring Ox was conducted on the farmland in front of the temple. A village elder led a plow ox adorned with red flowers on its horns and draped in a red cloth to the field, while a child dressed up as the God of Spring, whipped the ox. It signified the beginning of agricultural activities for the new year.

A cultural exchange activity was held in the temple after the ceremony. Scholars, international guests, and local residents engaged in discussion on intangible cultural heritage and solar term traditions.

The traditional Chinese solar calendar divides the year into 24 solar terms. In 2016, the 24 Solar Terms was inscribed on the Representative List of the UNESCO Intangible Cultural Heritage of Humanity.

Village in eastern China celebrates Start of Spring
Village in eastern China celebrates Start of Spring- China.org.cn

GCCL Wins 2025 Asia-Pacific Customer Value Leadership Award by Frost & Sullivan

–      GCCL’s “One-Stop Lab Solution” sets the industry benchmark with unmatched competitiveness and a dedication to global excellence.

–      Continuing its growth as a globally recognized leader in clinical sample analysis, driven by customer-centric values.

YONGIN, South Korea, Feb. 7, 2025 /PRNewswire/ — GCCL(Global Clinical Central Lab), a leading Korean clinical trial sample analysis company, reinforced its position in the global market by receiving Frost & Sullivan’s 2025 Best Practices Customer Value Leadership Award in the Asia-Pacific clinical sample analysis services industry.

Frost & Sullivan, a global-established growth consulting company, honors companies that demonstrate exceptional leadership, innovation, and performance through its annual Best Practices awards. The organizations excel in delivering outstanding value by assessing the market participants’ value. Using a rigorous evaluation process, Frost & Sullivan assesses criteria including growth potential, customer acquisition, customer experience, operational efficiency, and equity. Having excelled in these areas, GCCL earned this recognition for its comprehensive services, customer-centric approach, and technological leadership.

GCCL is one of the few clinical trial sample analysis service providers offering a “one-stop lab solution” that integrates central lab, bioanalysis lab, and BSL-3[i] lab services into a single, unified system. This consolidated approach minimizes sample movement between facilities, reducing logistics time and costs while ensuring sample stability. As a result, it enhances data reliability and strengthens the credibility of study outcomes. By leveraging cutting-edge analytical platforms and implementing its Lab Information Management System (LIMS), GCCL maintains high standards in global clinical research. With tailored solutions, GCCL delivers precision and efficiency in clinical trials, solidifying its position as a trusted partner in new drug development.

Frost & Sullivan highlighted GCCL’s integrated lab service model, highlighted that systematic quality control and industry-leading technological innovation were as key factors in earning the award. This recognition underscores GCCL’s leadership in the APAC region, showcasing its position as APAC’s and unmatched capabilities in clinical sample analysis.

Kwan-goo Cho, CEO of GCCL, stated, “The award is a global recognition of our efforts and achievements in prioritizing customer value and proof that GCCL has established itself as the solid leader in the market.” He added, “We will continue to drive technological innovation and improve service quality to meet the rising demand in global clinical trials and to lead in the role as a trusted partner for new drug development.”

GCCL is a Good Clinical Laboratory Practice (GCLP)-certified lab accredited by the Ministry of Food and Drug Safety of South Korea. The company provides clinical trial sample analysis services globally across all clinical trial phases(I-IV), leveraging advanced analytical platforms including ddPCR technology, and its specialized expertise in sample analysis and method development. Serving pharmaceutical and biotechnology companies as well as in Korea, Asia, and beyond, GCCL is committed to deliver world-class, customized clinical trial solutions.

[i] Bio safety Level 3

Contact:

Sandra Woo
hywoo@gccorp.com

Harry Hong
honghr@gccorp.com

Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China

Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients

First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects

SHANGHAI, Feb. 7, 2025 /PRNewswire/ — Today, Nuance Pharma (“Nuance”) announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

In June 2024, Ohtuvayre™ was approved in the United States and became commercially available in August. Ohtuvayre™ is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (“PDE3; PDE4”) that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule, delivered directly to the lungs through a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination.

The approval of Ohtuvayre™ in Macau SAR, China, was based on extensive data including the Global Phase 3 ENHANCE trials, the results of which were published in the American Journal of Respiratory and Critical Care Medicine. In the ENHANCE trials, OhtuvayreTM demonstrated clinical benefits both alone and when used with other maintenance therapies. OhtuvayreTM was well-tolerated in a broad population of subjects with moderate to severe COPD.

Mark Lotter, founder and Chief Executive Officer of Nuance Pharma, said: “We are pleased to announce that the Macau regulatory authority has approved the NDA of Ohtuvayre™, which also marks the first regulatory approval outside of the US. We are proud to provide access to this highly innovative COPD treatment to patients in Macau and beyond, for example through innovative policy in the Greater Bay Area (GBA). Respiratory disease is among Nuance’s core areas of focus, and through approval in Macao SAR and early access programs in Hainan BoAo and GBA, Nuance Pharma is looking forward to providing this novel, first-in-class treatment to patients in China, prior to our expected NDA submission in 2025 upon completion of the ENHANCE-CHINA trial.”

David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma, said: “We are very pleased that OhtuvayreTM is available to help patients still experiencing daily COPD symptoms. We are encouraged by the initial impact of OhtuvayreTM and believe its novel profile can re-define the COPD treatment paradigm.”

In Nov 2024, Nuance Pharma launched Ohtuvayre™ in China’s Hainan Boao Pilot Zone through early access program. In Sep 2024, Nuance Pharma completed recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD.

In 2021, Nuance Pharma entered into an agreement with Verona Pharma for the exclusive rights to develop and commercialize Ohtuvayre™ in Greater China (mainland China, Hong Kong, Macau and Taiwan).

About Ohtuvayre™ (ensifentrine)

Ohtuvayre™ is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre™ in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre™ met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function.

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. OhtuvayreTM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

About Nuance Pharma

Nuance Pharma is an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset portfolio. Focusing on specialty care, Nuance has established a differentiated combination of commercialized assets and innovative pipeline across respiratory, pain management, emergency care and iron deficiency anemia. With the mission to address critical unmet medical needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a global leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia as a region. For more information, please visit www.nuancepharma.com.

Forward-looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

TIER IV, Nihon Kotsu launch data collection project to enhance autonomous driving AI

TOKYO, Feb. 7, 2025 /PRNewswire/ — TIER IV, the pioneering force behind the world’s first open-source software for autonomous driving, and Nihon Kotsu, Tokyo’s largest taxi company, launched a pioneering project in February to collect driving data using taxis equipped with a data recording system (DRS) developed by TIER IV. The aim of the project is to develop generative AI that will enhance the safety and ride quality of autonomous driving.

Large-scale data captured during taxi operations will be shared with key industry partners in an effort to compile optimized datasets for autonomous driving AI, contributing to Japanese government initiatives to advance the deployment of Level 4 autonomous driving technologies.

Since November 2018, Nihon Kotsu and TIER IV have conducted experimental data collection for autonomous driving, formalizing their partnership in July 2024. TIER IV has also led a robotaxi proof of concept, integrating autonomous driving systems into vehicles and validating services such as ride-hailing apps, mapping technologies and operational support centers. These efforts recently gained support from Japan’s Ministry of Economy, Trade, and Industry under a subsidy program to promote digital transformation in the mobility sector.

A key element of the latest project with Nihon Kotsu is TIER IV’s Co-MLOps platform, which is designed to build high-quality datasets from large-scale driving data collected globally. By enabling efficient sharing of datasets among autonomous driving system developers, the platform aims to accelerate AI innovation and overcome the challenges often faced by individual companies working in isolation.

In this project, DRS-equipped taxis featuring advanced sensor systems critical for autonomous driving AI development will collect data across Greater Tokyo and that data will be shared with partner companies in the automotive sector and beyond. While previous data collection efforts relied on TIER IV test vehicles, Nihon Kotsu taxis are being used for this initiative, starting with five vehicles in February 2025, and eventually increasing to about 20.

Looking ahead, Nihon Kotsu and TIER IV will deepen their partnership, conducting pilot tests to accelerate the rollout of robotaxi services in Japan. Using data from tests initiated in November 2024, the companies plan to develop Level 4-equipped autonomous vehicles and gradually introduce services in multiple regions, with a primary focus on Tokyo.

In the initial phase, robotaxi services will be tested under a mobility hub model, with drivers stationed in the vehicles for safety assurance. This model aims to improve regional accessibility and evaluate operational frameworks for robotaxi deployments. The outcomes from vehicle development and operational evaluations will be shared as a TIER IV reference design – a blueprint for autonomous driving systems that not only lowers entry barriers for new businesses but also directly supports the Japanese government’s digital transformation goals in the mobility sector.

About TIER IV

TIER IV stands at the forefront of deep tech innovation, pioneering Autoware, the world’s first open-source software for autonomous driving. Harnessing Autoware, we build scalable platforms and deliver comprehensive solutions across software development, vehicle manufacturing, and service operations. As a founding member of the Autoware Foundation, we are committed to reshaping the future of intelligent vehicles with open-source software, enabling individuals and organizations to thrive in the evolving field of autonomous driving.
Autoware is a registered trademark of the Autoware Foundation.

About Nihon Kotsu

Company name: Nihon Kotsu Co., Ltd.
Establishment: April, 1928
President: Yasuharu Wakabayashi
Headquarters: 3-12 Kioicho, Kioicho Building, Chiyoda Ward, Tokyo, Japan
Business description: Taxi and limousine service
Website: https://www.nihon-kotsu.co.jp/

Media Contact
pr@tier4.jp

Business Inquires
co-mlops@tier4.jp

CleanMax and Amazon sign PPA for 100MW of Wind Energy

MUMBAI, India, Feb. 7, 2025 /PRNewswire/ — CleanMax, one of Asia’s leading renewable energy and net-zero solution provider for the Commercial and Industrial (C&I) sector and a Brookfield-backed company today announced a new Power Purchase Agreement with Amazon, which includes the development of 100 MW of renewable energy project.

This project will be connected to the national grid of India and will help meet the electricity consumption needs by Amazon’s operations. CleanMax will develop and operate the wind farm, which is expected to be operational by Q2 2026, generating roughly 355 million kWh of clean electricity annually and offsetting an estimated 252,000 tons of CO₂ annually — equivalent to planting nearly 14.8 million trees.

The agreement supports Amazon’s ‘Climate Pledge commitment’ in efforts to meet electricity needs of its operations and achieve net-zero carbon emissions across of its operations by 2040. This collaboration also underscores a larger trend of global tech companies deepening their presence, with an increasing commitment to sustainable practices and responsible corporate goals.

“CleanMax is proud to be enabling new renewable energy opportunities with Amazon. As a company that has always championed sustainability, CleanMax is elated to collaborate with Amazon to help decarbonize its operations while also advancing the green energy landscape,” said Kuldeep Jain, Managing Director of CleanMax.

About Clean Max Enviro Energy Solutions Pvt. Ltd. (CleanMax)

CleanMax with 2 GW of renewable assets (operating constructed capacity) is spread across Asia. CleanMax is a Brookfield backed company; a leading global alternative asset manager with over $1 trillion of assets under management. We focus on being the net-zero partner for corporates globally. Portfolio consists of rooftop solar projects, wind-solar hybrid farms & renewable energy certificates. Caters to industries such as Data Centres, Automotive, FMCG, Pharma etc. It has won the Transformational Business Awards 2018 by Financial Times (FT) and recognized for ‘Sustainable Performance in Net Zero’ at the Sustainability Conclave & Awards (2024)- India.

About  Amazon 

Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfilment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit aboutamazon.in and follow @AmazonNews

Contacts:
Ms. Sonali Charkha
+91-88888 37990
sonali.charkha@cleanmax.com


Cloud Market Jumped to $330 billion in 2024 – GenAI is Now Driving Half of the Growth

RENO, Nev., Feb. 7, 2025 /PRNewswire/ — New data from Synergy Research Group shows that Q4 enterprise spending on cloud infrastructure services was $91 billion worldwide, up $17 billion or 22% from the fourth quarter of 2023. The full-year 2024 market reach $330 billion, up $60 billion from 2023 and an increase of $102 billion from 2022. It is notable that ChatGPT was launched at the end of 2022, and generative AI services and technology have helped to propel the market since then. Synergy data and analysis shows that generative AI has driven half of the market growth over the last two years, through a combination of new GenAI platform services, GPU as a service, and enhancements to a wide range of other cloud services. In terms of competitive positioning, Amazon maintains a strong lead in the market though Microsoft and Google once again had a higher percentage of growth. Their Q4 worldwide market shares were 30%, 21% and 12% respectively. Among the tier two cloud providers, those with the highest year-on-year growth rates include CoreWeave, Oracle, Snowflake, Cloudflare and Databricks. Notably, CoreWeave has now broken into the top twenty ranking of cloud providers thanks to its AI and GPU services.

Cloud Services Growth
Cloud Services Growth

With most of the major cloud providers having now released their earnings data for Q4, Synergy estimates that quarterly cloud infrastructure service revenues (including IaaS, PaaS and hosted private cloud services) were $90.6 billion, with full-year 2024 revenues reaching $330.4 billion. Public IaaS and PaaS services account for the bulk of the market and those grew by 24% in Q4. The dominance of the major cloud providers is even more pronounced in public cloud, where the top three account for 68% of the market. Geographically, the cloud market continues to grow strongly in all regions of the world. When measured in local currencies the major countries with the strongest growth included Brazil, Spain, Italy, India and Japan, all growing at rates above the worldwide average. The US remains by far the largest cloud market, with its scale far surpassing the whole APAC region. The US market grew by 23% in Q4. In Europe the largest cloud markets are the UK and Germany, but the big markets with the highest growth rates were Ireland, Spain and Italy.

“Q4 was another strong quarter for cloud services, helping to drive a full-year growth rate that was a full four percentage points higher than 2023. For such a big market that is an impressive acceleration of growth,” said John Dinsdale, a Chief Analyst at Synergy Research Group. “How much of that was down to AI? ChatGPT was launched at the end of 2022 and helped to bolster service development through 2023 and then boost more aggressive market growth through 2024. Our assessment is that since ChatGPT was launched, GenAI has been responsible for at least half of the increase in cloud service revenues. That has come from either newly launched GenAI/GPU services or from AI-driven improvements to existing cloud services.”

About Synergy Research Group

Synergy Research Group provides quarterly market share analysis and forecasts for Communications and Cloud related industries. Our data and analysis is provided to clients through Synergy’s unique research SaaS platform, SIA™, which enables intuitive access to complex and fast-moving data sets.

Synergy’s data analytics and analysis have been widely recognized worldwide for over 25 years and are frequently used by global industry leaders, governments, and financial institutions.

To speak to an analyst or to find out more about how to access Synergy’s in-depth market data, please contact Heather Gallohgallo@srgresearch.com or at 775-785-3113.